https://scholars.lib.ntu.edu.tw/handle/123456789/635088
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Lai, Chih-Cheng | en_US |
dc.contributor.author | Chen, Wei-Chih | en_US |
dc.contributor.author | Kuo, Li-Kuo | en_US |
dc.contributor.author | Wang, Yao-Tung | en_US |
dc.contributor.author | Fu, Pin-Kuei | en_US |
dc.contributor.author | SHIH-CHI KU | en_US |
dc.contributor.author | Fang, Wen-Feng | en_US |
dc.contributor.author | Chen, Chin-Ming | en_US |
dc.contributor.author | Tu, Chih-Yen | en_US |
dc.contributor.author | Cheng, Wen-Chien | en_US |
dc.contributor.author | Chen, Chia-Hung | en_US |
dc.date.accessioned | 2023-09-05T07:39:28Z | - |
dc.date.available | 2023-09-05T07:39:28Z | - |
dc.date.issued | 2023-07-14 | - |
dc.identifier.issn | 00257974 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/635088 | - |
dc.description.abstract | The objective was to compare the clinical efficacy of cefoperazone-sulbactam with piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP). The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical outcomes were compared for patients who received either cefoperazone-sulbactam or piperacillin-tazobactam in the treatment of SCAP. A total of 815 SCAP patients were enrolled. Among them, 343 received cefoperazone-sulbactam, and 472 received piperacillin-tazobactam. Patients who received cefoperazone-sulbactam presented with higher Charlson Comorbidity Index scores. (6.20 ± 2.77 vs 5.72 ± 2.61; P = .009). The clinical cure rates and effectiveness for patients receiving cefoperazone-sulbactam and piperacillin-tazobactam were 84.2% versus 80.3% (P = .367) and 85.4% versus 83.3% (P = .258), respectively. In addition, the overall mortality rate of the cefoperazone-sulbactam group was 16% (n = 55), which was also comparable to the piperacillin-tazobactam group (17.8%, n = 84, P = .572). The primary clinical outcomes for patients receiving cefoperazone-sulbactam were superior compared to those receiving piperacillin-tazobactam after adjusting disease severity status. The clinical efficacy of cefoperazone-sulbactam in the treatment of adult patients with SCAP is comparable to that of piperacillin-tazobactam. After adjusting for disease severity, cefoperazone-sulbactam tended to be superior to piperacillin-tazobactam. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Medicine | en_US |
dc.subject | acquired pneumonia | cefoperazone | piperacillin | severe community | sulbactam | tazobactam | en_US |
dc.title | The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1097/MD.0000000000034284 | - |
dc.identifier.pmid | 37443505 | - |
dc.identifier.scopus | 2-s2.0-85164843711 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85164843711 | - |
dc.relation.journalvolume | 102 | en_US |
dc.relation.journalissue | 28 | en_US |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-4123-0967 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。